An interventional study of Intertransverse process block and Sham block in Chronic Postsurgical Pain, sponsored by Chinese University of Hong Kong. Recruiting at 1 site in Hong Kong. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-18.
Sponsored by Chinese University of Hong Kong · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Pain, Postoperative with a site in Hong Kong — 6 open to participants now, 6 under way, 3 of them phase 3. Pain, Postoperative · Hong Kong.
Among the 21 studies in Pain, Postoperative with a site in Hong Kong, this one is the 8th largest by planned enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2026, is one of 6 with no phase, and was the 18th registered.
5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.
Browse Pain, Postoperative studies →6 of the 21 studies in Pain, Postoperative with a site in Hong Kong are open now. Recruiting first, the newest first:
The University of Hong Kong · Sites in Hong Kong
Ages 18–90
Chinese University of Hong Kong · Sites in Hong Kong
Ages 18+
The University of Hong Kong · Sites in Hong Kong
Ages 18–80
Monash University · Sites in Hong Kong, Australia, New Zealand and 1 more country
Ages 18+ · Women only
The University of Hong Kong · Sites in Hong Kong
Ages 18–80
A study can be open while its sites in Hong Kong have not opened yet or have stopped. Only those recruiting at a site in Hong Kong →
Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 96 is above the median of 75 across 4,859 interventional studies indexed under Pain, Postoperative.
Median enrollment 90 across the 19 interventional studies, 1,099 across the 2 observational. Of the 13 that completed or were terminated, 1 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 21 have an industry lead sponsor. The 6 most frequent:
Chinese University of Hong Kong is the lead sponsor of 1,458 studies on the registry; 478 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Chinese University of Hong Kong has 7 studies filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
2 of the studies in Pain, Postoperative with a site in Hong Kong that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06740214Phase 3The University of Hong KongAnalgesic Efficacy of Different Liposomal Bupivacaine Doses in the Adductor Canal Block for Total Knee Arthroplasty | 2027-06-30 |
| NCT06946290Chinese University of Hong KongIntertransverse Process Block to Improve Quality of Recovery and Pain Management in Adult Cardiac Surgical Patients | 2027-01-02 |
Add all 2 to your calendar (.ics) → With an account.
Among the 21 studies in Pain, Postoperative with a site in Hong Kong, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate the efficacy of intertransverse process block (ITPB) in improving quality of recovery and potentially preventing chronic postsurgical pain (CPSP) in adult patients undergoing elective cardiac surgery (e.g., coronary artery bypass graft [CABG], valve repair/replacement, or combined CABG/valve procedures).
The main questions it aims to answer are:
Introduction:
The cornerstone of modern pain management in cardiac surgery lies in proactively preventing the development of chronic postsurgical pain (CPSP). This paradigm shift emphasizes pre-emptive interventions to disrupt the cascade of events and central sensitization that transform acute postoperative pain into a persistent, debilitating condition. CPSP, a significant and often underestimated consequence of cardiac surgery, affects a substantial proportion of patients, with prevalence rates ranging from 28% to 56% in the years following surgery. Its impact extends beyond mere discomfort, significantly impairing daily function, reducing quality of life, and imposing a substantial economic burden on the healthcare system.
The pathophysiology of CPSP involves a complex interplay of factors, with central sensitization playing a pivotal role. This process, characterized by heightened neuronal excitability within the central nervous system, amplifies pain signals and can lead to persistent pain even after the initial injury has healed. Therefore, a crucial aspect of CPSP prevention lies in disrupting the afferent nociceptive signals transmitted from the injured tissues to the spinal cord and brain, thereby preventing the establishment and perpetuation of central sensitization.
While opioids have traditionally been the mainstay of postoperative pain management, their use is not without significant drawbacks. Opioids can have dose-dependent side effects, including respiratory depression, nausea, and constipation. Furthermore, prolonged opioid use can lead to tolerance, opioid-induced hyperalgesia, and an increased risk of chronic opioid use. Recognizing these limitations, the current emphasis in pain management is on multimodal analgesia strategies that incorporate non-opioid medications and regional anaesthesia techniques to optimize pain control while minimizing the risks associated with opioid use.
Non-steroidal anti-inflammatory drugs (NSAIDs) offer a valuable adjunct in pain management, but their use in cardiac surgery is often limited due to concerns regarding bleeding complications and potential renal impairment. Other non-opioid analgesics, such as paracetamol and gabapentinoids, have shown limited efficacy in managing the intense pain associated with sternotomy. Regional anaesthesia techniques have emerged as promising strategies for both acute pain management and potential CPSP prevention in various surgical settings. Techniques such as epidural anaesthesia and paravertebral blocks have demonstrated efficacy in reducing postoperative pain intensity and opioid requirements. However, their application in cardiac surgery presents unique challenges. Epidural anaesthesia carries the risk of neuraxial hematoma due to systemic anticoagulation and heparinization, while paravertebral blocks may be associated with complications such as pneumothorax and pleural puncture. Erector spinae plane block (ESPB) has shown inconsistent results in reducing postoperative pain and morphine consumption in cardiac surgery. Parasternal plane blocks offer advantages over neuraxial techniques but may not adequately address visceral pain.
While regional anaesthesia is crucial for managing acute postoperative pain, its impact on CPSP remains largely unknown. The potential for regional anaesthesia to reduce CPSP has been identified as one of the top research priorities in anaesthesia and perioperative care. Intertransverse process block (ITPB) is a novel and promising alternative, targeting the paravertebral space through extra- paravertebral injection within the intertransverse tissue complex, posterior to the superior costotransverse ligament (SCTL). Recent MRI studies have demonstrated consistent spread of local anaesthetic to the ipsilateral intercostal, paravertebral spaces, neural foramina, and epidural space following ITPB, suggesting potential for both somatic and visceral analgesia. It demonstrated preferential spread of LA to the epidural space and neural foramina over the ESPB, and into the thoracic paravertebral space with effective analgesia after breast and video-assisted thoracoscopic surgeries. Compared to other regional techniques in cardiac surgery, ITPB may offer a simpler and safer approach with reduced risk of pleural puncture and bleeding. Therefore, this trial will assess the efficacy of ITPB in quality of recovery after cardiac surgery, and the potential to mitigate both acute and chronic postsurgical pain in cardiac surgical patients.
Study Design:
Single-centre, prospective, randomized, placebo-controlled, double-blinded trial
Randomization and Concealment Randomisation will be performed in 1:1 ratio using the REDCap randomisation module in the study database, allocating participants to either the ITPB (intervention) or control group in randomly permuted blocks of size four. Sequentially numbered, coded, sealed, opaque envelopes, each containing the group assignment of either interventional or control are then prepared by a third party who takes no further part in the study. The ITPB syringes will be prepared under strict aseptic conditions by a nurse not involved in the study, with blind labelling. The surgical team, blinded to group allocation, will perform standardised surgical procedures. Anaesthetists and nurses responsible for data collection in both ICU and wards are also blinded to the treatment allocation.
Anaesthesia and Interventions All patients receive standard cardiac surgery monitoring. General anaesthesia is induced with midazolam 0.01-0.05 mg/kg, fentanyl 2-5 mcg/kg, and rocuronium 0.5-1 mg/kg to facilitate intubation. Anaesthesia is maintained with sevoflurane and propofol infusion, targeting a Bispectral Index of 40-60. ITPB is performed after anaesthesia induction with the patient in lateral decubitus positioning. Intraoperative opioids (fentanyl and morphine) will be administered at the discretion of the anaesthesiologist. The postoperative analgesia protocol was identical in both study groups, including patient-controlled analgesia (PCA) morphine protocol for 72 hours after surgery, oral analgesics (paracetamol 1g every 6 hours, dihydrocodeine 30mg three times a day), and on-demand antiemetics (intravenous ondansetron 4mg every 8 hours). Rescue analgesics on top of the protocol regimen can be prescribed as needed. Upon ICU admission, propofol infusion is stopped to facilitate weaning from ventilator using Adaptive Support Ventilation (ASV), which adjusts the ventilation parameters depending on the patent's lung mechanics and effort. Pain will be assessed regularly in ICU and on the ward. Upon extubation, pain scores are assessed at 2-hour, 4-hour, 8-hour, 12-hour, 24-hour, 48-hour and 72-hour. Patients receive PCA morphine for moderate to severe pain. Nausea, vomiting and rescue antiemetics are documented.
Ultrasound Block Placement The intervention group received bilateral ITPB after GA induction, whilst sham blocks are performed in the control group. All blocks are performed by an anaesthesiologist who had previously performed ≥50 successful ITPB blocks, using Philips EPIQ ultrasound system, with a curved array transducer (C5-1), and 80mm echogenic nerve block needle (SonoTAP; PAJUNK, Germany). ITPB is performed with the patients positioned in a lateral decubitus position. The target intervertebral level (T4-5) is identified and marked in the preview ultrasound scan. The transducer is placed 2-3 cm lateral to the spinous process. Under strict asepsis, a single-level (T4-5) ultrasound-guided ITPB is performed with the in-plane insertion of the block needle from lateral to medial direction until its tip is at the medial aspect of the retro-SCTL space. After confirming the needle position by distension of the retro-SCTL space after a test bolus injection of 1-2 ml 0.9% normal saline, 20 ml 0.25% levobupivacaine or placebo is injected via the nerve block needle in small aliquots. The same procedure is repeated on the other side with the same volume of study medication. The time required to perform the block will be recorded as the time from insertion of block needle to removal from the patient after injection.
Data Collection All data is collected by research team members blinded to group assignment. Patient demographics and body mass index are recorded. Cumulated opioid consumption data and time to first morphine rescue are extracted from PCA pump. At 2-hour, 4-hour, 8-hour, 12-hour, 24-hour, 48-hour and 72-hour post-extubation, pain scores at rest and on coughing are quantified using NRS from 0 to 10. Zero represents no pain at all while 10 points represents the worst pain ever. The patients are asked to rate the overall satisfaction to pain management on a verbal analogue scale (0=worst possible, 100=best possible) at the predefined points. Any nausea and vomiting, and use of rescue antiemetics are documented. The Chinese validated QoR-15 will be completed at baseline (preoperatively) and postoperatively at 24-hour and 72-hour after extubation. The SF-MPQ- 2 and BPI will be used to evaluate the CPSP at 3-month, 6-month and 12-month after surgery.
Statistics and sample size calculation Sample size was calculated using G*Power software version 3.1.9.3 (Kiel University, Kiel, Germany), based on the QoR-15 score at 24 hours postoperatively the primary outcome. The minimum clinically important difference (MCID) for the QoR-15 score is eight points, and the typical standard deviation (SD) ranges from 10 to 16. Assuming a two-sided type I error of 0.05, type II error of 0.2, and a population variance of 144 (SD = 12), a sample size of 36 per group is required. Allowing for a 20% dropout rate, a total of 96 patients (48 patients per group) will provide 80% power to detect a mean difference of ≥8 points in the QoR-15 score at 24 hours between the two groups.
All outcomes will be analysed and reported on an intention-to-treat basis, with patients analysed according to their randomised group regardless of protocol adherence. A secondary per protocol analysis will be conducted for patients who do not adhere fully to the study protocol. Given the repeated measures of pain scores over time, which are correlated, Generalised Estimating Equation (GEE) models will be used to assess the time effects of postoperative analgesia. Categorical data will be reported as counts and percentages. Continuous variables will be presented as mean (standard deviation) or median (interquartile range), depending on normality assessed using the Shapiro-Wilk's test. Between-group comparison will be conducted using the independent sample t-test for parametric data and Mann-Whitney U test for nonparametric data. Categorical variables will be compared using the Chi-square test. Data analyses will be performed using SPSS 27.0 (IBM Corp, Armonk, NY), and GEE modelling will be conducted using Stata V.14 (Statam College Station, Texas, USA), with a Gaussian distribution, identify-link function, exchangeable correlation structure, and robust standard errors. A P-value of \<0.05 will be considered statistically significant, without adjusting for multiple comparisons.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intertransverse process block is performed on patients with injection of 20ml 0.25% levobupivacaine at the retro-SCTL space after a test bolus of 1-2ml 0.9% normal saline. The same procedure is repeated on the other side with same volume of study medication.
Procedure: Intertransverse process block
Sham intertransverse process block is performed on patients with injection of 20ml placebo at the retro-SCTL space after a test bolus of 1-2ml 0.9% normal saline. The same procedure is repeated on the other side with same volume of study medication.
Procedure: Sham block
All blocks are performed by an anaesthesiologist who had previously performed ≥50 successful ITPB blocks, using Philips EPIQ ultrasound system, with a curved array transducer (C5-1), and 80mm echogenic nerve block needle. ITPB is performed with the patients positioned in a lateral decubitus position. The target intervertebral level (T4-5) is identified and marked in the preview ultrasound scan. The transducer is placed 2-3 cm lateral to the spinous process. Under strict asepsis, a single-level (T4-5) ultrasound-guided ITPB is performed with the in-plane insertion of the block needle from lateral to medial direction until its tip is at the medial aspect of the retro-SCTL space. After confirming the needle position by distension of the retro-SCTL space after a test bolus injection of 1-2 ml 0.9% normal saline, 20 ml 0.25% levobupivacaine is injected via the nerve block needle in small aliquots. The same procedure is repeated on the other side with the same volume of study medication.
All blocks are performed by an anaesthesiologist who had previously performed ≥50 successful ITPB blocks, using Philips EPIQ ultrasound system, with a curved array transducer (C5-1), and 80mm echogenic nerve block needle (SonoTAP; PAJUNK, Germany). ITPB is performed with the patients positioned in a lateral decubitus position. The target intervertebral level (T4-5) is identified and marked in the preview ultrasound scan. The transducer is placed 2-3 cm lateral to the spinous process. Under strict asepsis, a single-level (T4-5) ultrasound-guided ITPB is performed with the in-plane insertion of the block needle from lateral to medial direction until its tip is at the medial aspect of the retro-SCTL space. After confirming the needle position by distension of the retro-SCTL space after a test bolus injection of 1-2 ml 0.9% normal saline, 20 ml placebo is injected via the nerve block needle in small aliquots. The same procedure is repeated on the other side with the same volume study drug.
Quality of recovery at 24 hours after extubation
The score ranges from 0 to 150, with higher scores associated with better quality of recovery. Though acute pain is identified as an important predictor for the development of CPSP, advanced pain management strategies have failed to reduce the overall incidence of CPSP, suggesting a complex underlying mechanism. Evidence have demonstrated that pain-related functional interference and patient-reported outcomes, such as quality of recovery, might be associated with the development of CPSP. Thus, the primary outcome of this study is the Quality of Recovery (QoR-15) score at 24 hours after extubation. QoR is recommended for patient's comfort after surgery, and is highly valid and reliable patient-centred outcome measure.
Time frame: 24 hours after extubation
Numerical rating scale
Pain scores after extubation. It is a 11-points scale from 0 to 10, with zero score means no pain, and 10 score means the worst pain ever
Time frame: 2-hour, 4-hour, 8-hour, 12-hour, 24-hour, 48-hour and 72-hour after extubation
Patient satisfaction with pain management
Assessment on patient satisfaction with pain management at predefined time point after extubation. The patients are asked to rate the overall satisfaction to pain management on a verbal analogue scale (0=worst possible, 100=best possible)
Time frame: 2-hour, 4-hour, 8-hour, 12-hour, 24-hour, 48-hour and 72-hour after extubation
Postoperative morphine consumption
Postoperative morphine consumption at predefined time point after extubation
Time frame: 2-hour, 4-hour, 8-hour, 12-hour, 24-hour, 48-hour and 72-hour after extubation
Time for first morphine rescue
Time for first morphine rescue (in minutes)
Time frame: Up to postoperative day 3, with time of first morphine required recorded
Intraoperative opioid consumption
Converted into morphine equivalence
Time frame: Intraoperative record
Duration of mechanical ventilation
Duration of mechanical ventilation required in postoperative period
Time frame: Up to postoperative day 1, ventilation requirement will be observed with duration of ventilation required after operation recorded.
Length of stay in ICU and hospital
Length of ICU and hospital stay postoperatively
Time frame: Up to 1 month after surgery, length of stay in intensive care unit and hospital will be recorded
Number of episodes of postoperative nausea and vomiting
Side effects associated with opioids such as postoperative nausea and vomiting (PONV)
Time frame: Perioperative up to 7 days
Percentage and number of patients having chronic post-surgical pain
Incidence of chronic post-surgical pain, which will be asked based on the definition of chronic post-surgical pain by International Association for Study of Pain (IASP)
Time frame: 3 month, 6 month and 12 month after surgery
Pain interference with SF-MPQ-2
Together 22-items, each item ranges from 0 to 10. The higher the score, the worst the outcome. Pain interference measured with Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2)
Time frame: 3 month after surgery
Pain interference with SF-MPQ-2
Together 22-items, each item ranges from 0 to 10. The higher the score, the worst the outcome. Pain interference measured with Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2)
Time frame: 6 month after surgery
Pain interference with SF-MPQ-2
Together 22-items, each item ranges from 0 to 10. The higher the score, the worst the outcome. Pain interference measured with Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2)
Time frame: 12 month after surgery
Pain interference with BPI
11-items, each item ranges from 0 to 10. The higher the score, the worst the outcome. Pain interference measured with Brief Pain Inventory (BPI) Interference Scale
Time frame: 3 month after surgery
Pain interference with BPI
11-items, each item ranges from 0 to 10. The higher the score, the worst the outcome. Pain interference measured with Brief Pain Inventory (BPI) Interference Scale
Time frame: 6 month after surgery
Pain interference with BPI
11-items, each item ranges from 0 to 10. The higher the score, the worst the outcome. Pain interference measured with Brief Pain Inventory (BPI) Interference Scale
Time frame: 12 month after surgery
Number of episodes requested antiemetics after surgery
The number of times the patient requesting antiemetic for nausea and vomiting will be documented
Time frame: Up to postoperative day 7
Plan to share: No
Started Jan 2026 (actual). Primary completion is estimated for Jan 2027, 12 months after the start.
Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 12 months is close to that.
Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chinese University of Hong Kong →